IFNG and cancer: The expression of siglec-15 (downregulated by IFN-γ) is negatively correlated with the expression of PD-L1 (upregulated by IFN-γ), suggesting that siglec-15 targeted therapy may be a complementary method for cancer patients who are refractory to PD-1/PD-L1-targeting therapies [15].